Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 801-282-5 | CAS number: 1034343-98-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key: repeated dose, inhalation, 28 d, rat, OECD 412, NOAEC ≥ 1.88 mg/m3 (Kim et al., 2016)
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study)
- Deviations:
- no
- GLP compliance:
- not specified
- Remarks:
- no information on GLP compliance available in this publication
- Limit test:
- no
- Specific details on test material used for the study:
- Aerosolized graphene nanoplatelets had various thicknesses, ranging from 0.350 to 0.380 nm. The TEM-EDS analysis indicated the presence of two elements (i.e. C and O), in the following atomic percentages:
C (96.28%) and O (3.72%).
- Surface area of particles: 750 m2/g
- Density: 0.2 g/mL
- Average lateral dimension: <2 µm
- Average thickness: 20-30 layers - Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- no details given
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: OrientBio (Seongnam, Korea)
- Age at study initiation: six weeks
- Fasting period before study:
- Housing: polycarbonate cages (maximum of three rats per cage) installed in individually ventilated cage racks
- Diet (e.g. ad libitum): rodent diet (Woojung BSC, Suwon, Korea) ad libitum
- Water (e.g. ad libitum): filtered water ad libitum
- Acclimation period: 2 weeks before initiating the inhalation exposure; during the acclimation period, the animals were trained to adapt to the nose-only inhalation chamber for 6 h/day
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ±0.65 °C
- Humidity (%): 56 ±0.08%
- Photoperiod (hrs dark / hrs light): 12-h light/dark cycle - Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose only
- Vehicle:
- clean air
- Mass median aerodynamic diameter (MMAD):
- 123 nm
- Geometric standard deviation (GSD):
- 3.63
- Remarks on MMAD:
- The MMAD, measured using a 13-stage DLPI cascade impactor, was 123 nm with a GSD of 3.63
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Nose-only exposure system (HCT, Incheon, Korea)
- System of generating particulates/aerosols: the graphene nanopowder was generated using an atomizer (AG-01, HCT, Icheon, Korea), with purified air as the carrier gas
- Air flow rate: The gas flow was maintained at 30 liters per minute (L/min) using a mass flow controller (MFC, FC-7810CD-4V, AERA, Tokyo, Japan), and the flow rate to each nose port was 1 L/min
- Method of particle size determination: measured with a scanning nanoparticle spectrometer (SNPS, HCT Co., Ltd., Icheon, Korea) and dust monitor (OPC, Model 1.1.09, Grimm Technologies Inc., Douglasville, GA, USA)
TEST ATMOSPHERE
- Brief description of analytical method used: The mass concentration of graphene was determined gravimetrically (as post-weight minus pre-weight) by sampling on a PC filter (polycarbonate filter, size: 27 mm and pore size 0.2 pm) and MSA Escort ELF sampling pump (MSA, Pittsburgh, PA, USA) from the top and bottom parts of the port, at a flow rate of 1.0 L/min.
- Samples taken from breathing zone: yes
VEHICLE (if applicable)
- Concentration of test material in vehicle: the suspension in water used to generate the aerosol contained fresh air for the control, 1.5 mg/mL for the low concentration, 5 mg/mL for the moderate concentration, and 16 mg/mL for the high concentration - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The number concentration of airborne graphene aerosols was measured with a condensation particle counter (CPC, model 3775, TSI Inc., Shoreview, MN, USA): see table 1 below (Concentration and size distribution of aerosolized graphene nanoparticles inside the nose-only exposure chambers)
- Duration of treatment / exposure:
- 28 days (5 days/week for 4 weeks)
- Frequency of treatment:
- The animals were exposed to the graphene nanopowder for 6 h/day for 5 days/week, for four weeks; the control group received filtered fresh air.
- Dose / conc.:
- 0.125 mg/m³ air (nominal)
- Remarks:
- target mass concentration - delivered mass concentration: 0.12 ± 0.00 mg/m³
- Dose / conc.:
- 0.5 mg/m³ air (nominal)
- Remarks:
- target mass concentration - delivered mass concentration: 0.47 ± 0.03 mg/m³
- Dose / conc.:
- 2 mg/m³ air (nominal)
- Remarks:
- target mass concentration - delivered mass concentration: 1.88 ± 0.18 mg/m³
- No. of animals per sex per dose:
- 15
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- The rats were divided into four groups: control (unexposed, n = 15), low concentration group (n = 15), moderate concentration group (n = 15), and high-concentration group (n = 15). For each group of 15 animals, 5 animals were killed 1-day post-exposure, 5 were killed 28-day post-exposure, and 5 were killed 90-day post-exposure. The animals were examined daily for any evidence of exposure-related toxic responses. The body weights were measured at the time of purchase, at the time of grouping, once during the inhalation period, and before necropsy. The food consumption (g/ rat/day) was measured once a week. At killing (1-, 28-, and 90-day post-exposure, n = 5 each), gross observations of the organs were recorded, plus the testes, kidneys, spleen, liver, lungs, and brain were all carefully removed and weighed. All animal testing protocols were approved by the Hanyang University's Institutional Animal Care and Use Committee.
The daily lung burden per rat was estimated for 6 h of continuous exposure, a minute ventilation of 0.19L/min, and the following aerosol properties (see Results section): particle MMAD of 123 nm, GSD 3.63, lung deposition efficiency of 7.7% based on MPPD (2002), and graphene aerosol concentrations were 1.88, 0.47, and 0.12mg/m3 for high, moderate, and low concentrations, respectively. The following calculations were made:
Daily deposited dose (mg/day) = average graphene aerosol concentration (mg/m3) x minute volume (L/min = 0.06 m3/h) x exposure duration (h/day) x deposition efficiency (1)
Deposition at the high dose = 1.88 x (0.19 x 0.06) x 6 x 0.077 = 0.0099 mg/day
Deposition at the moderate dose= 0.47 x (0.19 x 0.06) x 6 x 0.077 = 0.0025 mg/day
Deposition at the low dose = 0.12 x (0.19 x 0.06) x 6 x 0.077 = 0.0006 mg/day
Cumulative dose (mg)/animal = daily deposited dose (mg/day) x number of doses (days)
For high exposure: 0.0099 mg/day x 20 days = 0.198 mg
For moderate exposure: 0.0025 mg/day x 20 days = 0.05 mg
For low exposure: 0.0006 mg/day x 20 days = 0.012 mg - Positive control:
- no details given
- Observations and examinations performed and frequency:
- The animals were examined daily for any evidence of exposure-related toxic responses.
The body weights were measured at the time of purchase, at the time of grouping, once during the inhalation period, and before necropsy.
The food consumption (g/rat/day) was measured once a week.
At killing (1-, 28-, and 90-day post-exposure, n = 5 each), gross observations of the organs were recorded, plus the testes, kidneys, spleen, liver, lungs, and brain were all carefully removed and weighed.
All animal testing protocols were approved by the Hanyang University's Institutional Animal Care and Use Committee. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Other examinations:
- After collecting the blood, the rats were killed by enotobar anasthesia, and the adrenal glands, bladder, testes, epididymis, heart, thymus, thyroid gland, trachea, esophagus, prostate, lungs, nasal cavity, kidneys, spleen, liver, pancreas, and brain were carefully removed. These organs were then weighed and fixed in a 10% formalin solution containing neutral phosphate-buffered saline (PBS). The organs were embedded in paraffin and stained with hematoxylin and eosin (BBC biochemical, Washington, DC). All the animal organs were examined using light microscopy. At killing, the left lungs were removed and fixed in a 10% formalin solution (BBC biochemical, Washington, DC) containing neutral PBS under 25 cm of water pressure for the histopathological evaluation. Thereafter, the lungs were embedded in paraffin, stained with hematoxylin and eosin, and examined under a light microscope. In addition, the graphene imaging was examined using a high-resolution illuminator (Cytoviva, Auburn, AL, USA) attached to a dark field microscope.
- Statistics:
- The statistical analysis of outcome parameters was performed using SPSS version19 (SPSS Inc., Chicago, IL). The statistical evaluation was performed using an analysis of variance (ANOVA) following multiple comparison tests using Duncan's method. The level of statistical significance was set at p < 0.05 and p < 0.01.
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Significant body weight losses were observed in the moderate-concentration group at 2 weeks and in the high-concentration group at 1, 5, 6, 11, and 13 weeks from the start of the exposure when compared with the control.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- effects observed, treatment-related
- Description (incidence and severity):
- Significant decreases in food consumption were noted in the low-concentration group at 2, 6, 12, 16, and 17 weeks and in the high-concentration group at 1, 7, 9, 12, 13, 14, 16, and 17 weeks from the start of the exposure when compared with the control.
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- No concentration-related changes in the blood biochemical parameters were observed.
The hematology values at the 1-day post-exposure and 90-day post-exposure did not show any significant changes in the hematological parameters when compared with the control.
The thrombin and activated partial thrombo-plastin times were measured for the blood at 1-day post-exposure and at 90-day post-exposure to evaluate the effect of the graphene exposure on blood coagulation; yet, no significant effects were found.
The blood glucose and total bilirubin (TBIL) were significantly increased in the moderate-concentration group, while the blood potassium was significantly decreased in the moderate-concentration group at the 1-day post-exposure.
The LDH (lactate dehydrogenase) was significantly decreased in the moderate-concentration group, the TBIL and chloride significantly increased in the high-concentration group, and the potassium significantly decreased in the high-concentration group when compared with the control at the 28-day post-exposure.
The blood urea nitrogen (BUN) was significantly decreased in the moderate-concentration group, the sodium (Na) significantly increased in the low-concentration group, chloride (Cl) was significantly increased in the high-concentration group, and the ratio of albumin to glucose was also significantly increased in the moderate-concentration group when compared with the control at 90-day post-exposure. - Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Effects on BAL fluid
The BUN, UrDF, LDH, mALB, and mTP were all measured in the BAL fluid from the rat lungs. The mALB was significantly decreased in the moderate-concentration group and the LDH significantly increased in the low-concentration group at 28-day post-exposure when compared with the control. No concentration-related effects were observed for the inflammatory biomarkers in the BAL fluid (Table 3). Furthermore, no other oxidative stress markers, such as H2O2, GSH, and MDA, measured in the BAL fluid were significantly elevated after the 1-day post-exposure or 28- and 90-day post-exposure, indicating the graphene exposure had no effect on oxidative stress (Table 3). Notably, the MDA levels at 90-day post-exposure were significantly lower in the low- and moderate-concentration groups relative to the control. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not specified
- Immunological findings:
- no effects observed
- Description (incidence and severity):
- Various cytokines were measured, including the granulocyte-colony stimulating factor, interferon-gamma, IL-1P, IL-6, IL-18, monocyte chemotactic protein-1, macrophage-colony stimulating factor, macrophage inflammatory protein-1, TNF-a, and vascular endothelial growth factor (VEGF) in the lung tissue lysates and TNF-a, IL-18, VEGF (ng/mL/UrDF), and transforming growth factor-beta1 (ng/mL/UrDF) in the BAL fluid. The cytokines measured in the lung lysates at 1-day post-exposure and 28- and 90-day post-exposure did not show any significant changes.
In BAL fluid the total cell counts and macrophage counts were significantly decreased in all the exposed groups at the 1-day postexposure and 28-day post-exposure when compared with the control (Table 2). The lymphocyte counts were also significantly decreased in the all exposed groups at the 1-day postexposure when compared with the control (Table 2). - Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- A significant organ weight loss was observed for the thymus in the high-concentration group when compared with the control after the 28-day graphene exposure.
Significant organ weight losses were observed for the liver in the moderate-concentration group, and for the left lung in the low-and moderate-concentration groups when compared with the control at 28-day post-exposure.
The brain weight was significantly increased in the high-concentration group, and the thymus weight significantly increased in the low-concentration group when compared with the control at 90-day post-exposure. - Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- The gross findings for the rat organs, including the testes, kidneys, spleen, liver, lungs, thymus, eyeballs, and brain, after the 28-day graphene exposure and during the 90-day recovery period
revealed no particular changes resulting from the graphene exposure when compared to the control. - Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- No inflammatory-related histological evidence, such as the increase and migration of PMN cells or proliferation of pneumocytes, a change in the thickness of the alveolar wall, or the formation of granulomatous regions, were observed in the lungs at 1-day post-exposure, and 28- and 90-day post-exposure.
Black particles ingested by the alveolar macrophages were observed at 1-day post-exposure and at 28- and 90-day post-exposure. Translocation of graphene was observed in lung-associated lymph nodes at 1-day post-exposure and at 28- and 90-day post-exposure. Hyperspectral images taken at 1-day post-exposure and at 28-and 90-day post-exposure showed a concentration-dependent deposition of graphene in mostly lung macrophages and some deposition in lung epithelial cells. The ingested graphene in the lung macrophages persisted even after the 90-day post-exposure period. - Histopathological findings: neoplastic:
- not specified
- Other effects:
- no effects observed
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1.88 mg/m³ air (analytical)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- clinical biochemistry
- histopathology: neoplastic
- immunology
- Critical effects observed:
- no
- Conclusions:
- NOAEL of no less than 1.88 mg/m3.
- Executive summary:
Study design
The current study evaluated subacute inhalation toxicity of graphene according to the OECD TG 412 (28-day study, OECD 2009). In this study, male Sprague-Dawley rats were subjected to inhalation exposure to 0.12, 0.47 and 1.88 mg/m3 of graphene nanomaterials for 28 days (6 h/day, 5 days/week, for 4 weeks) and then allowed to recover for 28 or 90 days.
Results
No dose-dependent effects were recorded up to the highest test concentration of graphene for the body weights, organ weights, bronchoalveolar lavage fluid inflammatory markers, and blood biochemical parameters at 1-day post-exposure and 28-day post-exposure. The inhaled graphenes were mostly ingested by macrophages yet there was no increase in the inflammatory cell numbers, markers, and cytokines resulting from the graphene-ingested lung macrophages. No distinct lung pathology was observed at the 1-, 28- and 90-day post-exposure. The inhaled graphene was translocated to lung lymph nodes.
Conclusion
The results of this 28-day inhalation study suggests a low toxicity of graphene and a NOAEL of no less than 1.88 mg/m3.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEC
- 1.88 mg/m³
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- A GLP study according to OECD TG 412 is available with the test item. Therefore, the quality of the database is high.
Additional information
Repeated dose toxicity: inhalation
Study design
The current study evaluated subacute inhalation toxicity of graphene according to the OECD TG 412 (28-day study, OECD 2009). In this study, male Sprague-Dawley rats were subjected to inhalation exposure to 0.12, 0.47 and 1.88 mg/m3of graphene nanomaterials for 28 days (6 h/day, 5 days/week, for 4 weeks) and then allowed to recover for 28 or 90 days.
Results
No dose-dependent effects were recorded up to the highest test concentration of graphene for the body weights, organ weights, bronchoalveolar lavage fluid inflammatory markers, and blood biochemical parameters at 1-day post-exposure and 28-day post-exposure. The inhaled graphenes were mostly ingested by macrophages yet there was no increase in the inflammatory cell numbers, markers, and cytokines resulting from the graphene-ingested lung macrophages. No distinct lung pathology was observed at the 1-, 28- and 90-day post-exposure. The inhaled graphene was translocated to lung lymph nodes.
Conclusion
The results of this 28-day inhalation study suggests a low toxicity of graphene and a NOAEL of no less than 1.88 mg/m3.
Justification for classification or non-classification
Based on the results of the key study for repeated dose toxicity: inhalation, the registered substance is not subject to classification as toxic after repeated inhalation with Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.